The disappointing clinical trial outcomes from using NFκB inhibitor in treatment of metastatic BC patients (Yang et al, 2006; Cresta et al, 2008) indicate that BC chemotherapy cannot be efficiently improved by only targeting NFκB pathway. Here, NFKB1 is linked to breast cancer.